Nifedipine intake increases the risk for periodontal destruction in subjects with type 2 diabetes mellitus

Journal of Periodontology

Volumn 79, Issue 11, 2008, Pages 2054-2059

  Li, Xiao ^a,b   Luan, Qingxian ^a,d   Wang, Xingyu ^c   Sha, Yueqin ^a   He, Lu ^a   Cao, Caifang ^a   Jin, Lijian ^b  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c Beijing Hypertension Prevention and Management Institute   (China)

^d NONE   (China)

Author keywords

Diabetes; Epidemiology; Periodontitis; Risk factors

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MIDDLE AGED; PERIODONTAL DISEASE; PERIODONTICS; RISK FACTOR; SINGLE BLIND PROCEDURE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CALCIUM CHANNEL BLOCKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; PERIODONTAL DISEASES; PERIODONTAL INDEX; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SINGLE-BLIND METHOD;

EID: 55749101608     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.080033     Document Type: Article

References (36)

1. Ellis JS, Seymour RA, Steele JG, Robertson P, Butler TJ, Thomason JM. Prevalence of gingival overgrowth induced by calcium channel blockers: A community-based study. J Periodontol 1999;70:63-67.
2. Miranda J, Brunet L, Roset P, Berini L, Farré M, Mendieta C. Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol 2001;72:605-611.
3. Takeuchi R. The effect of basic fibroblast growth factor on cell cycle in human gingival fibroblasts from nifedipine responder and non-responder. J Oral Sci 2004;46:37-44.
4. Fujimori Y, Maeda S, Saeki M, Morisaki I, Kamisaki Y. Inhibition by nifedipine of adherence- and activated macrophage-induced death of human gingival fibroblasts. Eur J Pharmacol 2001;415:95-103.
5. Nurmenniemi PK, Pernu HE, Laukkanen P, Knuuttila ML. Macrophage subpopulations in gingival overgrowth induced by nifedipine and immunosuppressive medication. J Periodontol 2002;73:1323-1330.
6. Huang WT, Lu HK, Chou HH, Kuo MY. Immunohistochemical analysis of Th1/Th2 cytokine profiles and androgen receptor expression in the pathogenesis of nifedipine-induced gingival overgrowth. J Periodontal Res 2003;38:422-427.
7. Trackman PC, Kantarci A. Connective tissue metabolism and gingival overgrowth. Crit Rev Oral Biol Med 2004;15:165-175.
8. Duriez J, Flautre B, Blary MC, Hardouin P. Effects of the calcium channel blocker nifedipine on epiphyseal growth plate and bone turnover: A study in rabbit. Calcif Tissue Int 1993;52:120-124.
9. Shih TT, Chang CJ, Tseng WY, et al. Effect of calcium channel blockers on vertebral bone marrow perfusion of the lumbar spine. Radiology 2004;231:24-30.
10. Brkic Z. Histopathologic investigations of nifedipine-induced gingival hyperplasia in Wistar rats. Vojnosanit Pregl 2005;62:207-211.
11. Spolidorio LC, Spolidorio DM, Nassar PO, Nassar CA, Holzhausen M, Almeida OP. Influence of age on combined effects of cyclosporin and nifedipine on rat alveolar bone. J Periodontol 2004;75:268-272.
12. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27:813-823.
13. Cohen DW, Friedman LA, Shapiro J, Kyle GC, Franklin S. Diabetes mellitus and periodontal disease: Two-year longitudinal observations. I. J Periodontol 1970;41:709-712.
14. Cianciola LJ, Park BH, Bruck E, Mosovich L, Genco RJ. Prevalence of periodontal disease in insulin-dependent diabetes mellitus (juvenile diabetes). J Am Dent Assoc 1982;104:653-660.
15. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: An epidemiologic perspective. Ann Periodontol 2001;6:99-112.
16. Sastrowijoto SH, Hillemans P, van Steenbergen TJ, Abraham-Inpijn L, de Graaff J. Periodontal condition and microbiology of healthy and diseased periodontal pockets in type 1 diabetes mellitus patients. J Clin Periodontol 1989;16:316-322.
17. Zambon JJ, Reynolds H, Fisher JG, Shlossman M, Dunford R, Genco RJ. Microbiological and immunological studies of adult periodontitis in patients with noninsulin-dependent diabetes mellitus. J Periodontol 1988;59:23-31.
18. Nishimura F, Iwamoto Y, Soga Y. The periodontal host response with diabetes. Periodontol 2000 2007;43:245-253.
19. Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol 2000 2007;44:127-153.
20. Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 1986;63:478-484.
21. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 1988;240:1546-1548.
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-553.
23. Silness J, Löe H. Periodontal disease in pregnancy. II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand 1964;22:121-135.
24. Curilovic Z, Mazor Z, Berchtold H. Gingivitis in Zurich schoolchildren. A reexamination after 20 years. SSO Schweiz Monatsschr Zahnheilkd 1977;87:801-808.
25. Hujoel PP, Drangsholt M, Spiekerman C, DeRouen TA. Periodontitis-systemic disease associations in the presence of smoking - Causal or coincidental? Periodontol 2000 2002;30:51-60.
26. Li X, Luan Q, Li P. Analysis of risk indicator for nifedipine-induced gingival hyperlasia (in Chinese). Zhonghua Kou Qiang Yi Xue Za Zhi 2007;42:677-680.
27. Meisel P, Schwahn C, John U, Kroemer HK, Kocher T. Calcium antagonists and deep gingival pockets in the population-based SHIP study. Br J Clin Pharmacol 2005;60:552-559.
28. King GN, Fullinfaw R, Higgins TJ, Walker RG, Francis DM, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporin-A and calcium antagonists. J Clin Periodontol 1993;20:286-293.
29. Turkmen A, Ak G, Furuncuoglu Y, et al. Relationship between gingival hyperplasia and class II histocompatibility antigens in renal transplant recipients. Nephron 2000;84:29-31.
30. Jin LJ, Chiu GK, Corbet EF. Are periodontal diseases risk factors for certain systemic disorders - What matters to medical practitioners? Hong Kong Med J 2003;9:31-37.
31. Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent diabetes mellitus. J Periodontol 1991;62:123-131.
32. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M. Glycemic control and alveolar bone loss progression in type 2 diabetes. Ann Periodontol 1998;3:30-39.
33. Papapanou PN. Periodontal diseases: Epidemiology. Ann Periodontol 1996;1:1-36.
34. Bullón P, Machuca G, Armas JR, Rojas JL, Jiménez G. The gingival inflammatory infiltrate in cardiac patients treated with calcium antagonists. J Clin Periodontol 2001;28:897-903.
35. Kiran M, Arpak N, Unsal E, Erdogan MF. The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus. J Clin Periodontol 2005;32:266-272.
36. Grossi SG. Treatment of periodontal disease and control of diabetes: An assessment of the evidence and need for future research. Ann Periodontol 2001;6:138-145.